

China Massive Health Industry Report (2016–2021), Market Outlook and Investment Opportunity

目 录

CONTENTS

Chapter 1: Background of development of China's massive health industry

- 1.1 scope of research of massive health industry
 - 1.1.1 scope of massive health
 - 1.1.2 scope of massive health industry
 - 1.1.3 scope of massive health strategy
- 1.2 analysis of development environment of China's massive health industry
 - 1.2.1 policy environment of massive health industry
 - 1.2.2 economic environment of massive health industry
 - 1.2.3 social environment of massive health industry
- 1.3 analysis of comprehensive benefits of massive health strategy
 - 1.3.1 analysis of economic benefit of massive health industry
 - 1.3.2 analysis of social benefit of massive health industry
 - 1.3.3 analysis of marketing benefit of massive health industry

Chapter 2: Analysis of China's pharmaceutical companies into massive health industry

- 2.1 policy environment for pharmaceutical companies into massive health
 - 2.1.1 interpretation of national supportive policies and regulations
 - 2.1.2 government's positioning towards massive health
 - 2.1.3 Forward's prediction of massive health policy for future years
- 2.2 status quo of pharmaceutical companies into massive health industry
 - 2.2.1 overview of China's pharmaceutical companies to enter massive health
 - 2.2.2 advantages of China's pharmaceutical companies to enter massive health
 - 2.2.3 analysis of China's pharmaceutical companies that have entered massive health
 - 2.2.4 analysis of scale of massive health market of China's pharmaceutical companies
 - 2.2.5 analysis of profit of China's pharmaceutical companies to enter massive health
 - 2.2.6 product distribution of China's pharmaceutical companies to enter massive health
 - 2.2.7 channel selection of China's pharmaceutical companies to enter massive health
- 2.3 channel strategy of pharmaceutical companies into massive health
 - 2.3.1 analysis of drugstore chain channel
 - (1) analysis of advantages and disadvantages of drugstore chain channel
 - (2) cases and the effectiveness of drugstore chain channel
 - (3) reference of experience of selection of drugstore chain channel
 - (4) analysis of feasibility of selection of drugstore chain channel
 - 2.3.2 analysis of traditional supermarket channel
 - (1) entry barriers of traditional supermarket channel
 - (2) degree of monopoly of traditional supermarket channel
 - (3) analysis of advantages and disadvantages of traditional supermarket channel
 - (4) cases and the effectiveness of traditional supermarket channel
 - (5) reference of experience of selection of traditional supermarket channel
 - (6) analysis of feasibility of selection of traditional supermarket channel
 - 2.3.3 analysis of emerging e-commerce channel
 - (1) development pace of emerging e-commerce channel
 - (2) analysis of advantages and disadvantages of emerging e-commerce channel
 - (3) points of selection of emerging e-commerce channel
 - (4) analysis of feasibility of selection of emerging e-commerce channel
- 2.4 reference of experience of case of pharmaceutical companies to enter massive health industry
 - 2.4.1 reference of experience of success stories of Yunnan Baoyao
 - 2.4.2 reference of experience of success stories of Wong Lo Kat
- 2.5 ideas on pharmaceutical companies to enter massive health industry and forecast
 - 2.5.1 analysis of ideas on pharmaceutical companies to enter massive health industry

- (1) analysis of ideas on product selection
- (2) analysis of ideas on product positioning
- (3) analysis of ideas on channel selection
- (4) analysis of ideas on brand marketing
- (5) analysis of ideas on marketing
- (6) analysis of ideas on market competition

2.5.2 Forward's forecast of prospects of pharmaceutical companies to enter massive health industry

Chapter 3: Analysis of transformation of China's drugstore chain into major health pharmacy

3.1 status quo of transformation of drugstore chain into major health pharmacy

- 3.1.1 overview of transformation of drugstore chain into major health pharmacy
- 3.1.2 inevitability of transformation of drugstore chain into major health pharmacy
- 3.1.3 analysis of transformed major health pharmacy
- 3.1.4 analysis of scale of major health products market of drugstore chain
- 3.1.5 profit changes of transformation of drugstore chain into major health pharmacy
- 3.1.6 product structure of transformation of drugstore chain into major health pharmacy

3.2 main models of transformation of drugstore chain into major health pharmacy

- 3.2.1 introduction of major health product model
- 3.2.2 introduction of major health service model
- 3.2.3 introduction of the "shop in shop" model

3.3 analysis of store display of transformation of drugstore chain into major health pharmacy

- 3.3.1 status quo of store display of major health products
- 3.3.2 research of effect of store display of major health products
- 3.3.3 association between display of major health products and performance
- 3.3.4 advice for best display solution of major health products

3.4 reference of experience of case of transformation of drugstore chain into major health pharmacy

3.4.1 reference of success experience of transformation of drugstore chain into major health pharmacy

3.4.2 reference of failed cases of transformation of drugstore chain into major health pharmacy

- (1) Shenxin Century Health New Concept Pharmacy
- (2) Yangpu Store of Shanghai Kaixinren Pharmacy
- (3) Hangzhou Jiuzhou Pharmacy Store
- (4) Wuxi Yanshoutang Pharmacy
- (5) Wuxi Mingda Pharmacy

3.5 ideas on transformation of drugstore chain into major health pharmacy and forecast

- 3.5.1 analysis of ideas on transformation of drugstore chain into major health pharmacy
- 3.5.2 Forward's forecast of transformation of drugstore chain into major health pharmacy

Chapter 4: Investment potential of subdivided markets of China's massive health industry

4.1 analysis of investment potential of toiletries market

- 4.1.1 status quo of development of toiletries market
 - (1) scale of toiletries market
 - (2) earnings of toiletries market
 - (3) competitive landscape of toiletries market
 - (4) risks of investment of toiletries market
- 4.1.2 overview of development of major health toiletries
- 4.1.3 scale of major health toiletries market
- 4.1.4 earnings of major health toiletries
- 4.1.5 investment potential of subdivided products of major health toiletries
 - (1) investment potential of shampoo
 - (2) investment potential of shower gel
 - (3) investment potential of hand sanitizer
 - (4) investment potential of soap
- 4.1.6 forecast of development of major health toiletries

4.2 analysis of investment potential of daily chemical products market

- 4.2.1 status quo of development of daily chemical products market
 - (1) scale of daily chemical products market
 - (2) earnings of daily chemical products market
 - (3) competitive landscape of daily chemical products market
 - (4) risks of investment of daily chemical products market

- 4.2.2 overview of development of major health daily chemical products
- 4.2.3 scale of major health daily chemical products market
- 4.2.4 earnings of major health daily chemical products
- 4.2.5 investment potential of subdivided products of major health daily chemical products
 - (1) investment potential of cosmetics
 - (2) investment potential of detergent
 - (3) investment potential of dental supplies
 - (4) investment potential of other cosmetic products
- 4.2.6 forecast of development of major health daily chemical products
- 4.3 analysis of investment potential of cosmeceutical products market**
- 4.3.1 status quo of development of cosmeceutical products market
 - (1) scale of cosmeceutical products market
 - (2) earnings of cosmeceutical products market
 - (3) competitive landscape of cosmeceutical products market
 - (4) risks of investment of cosmeceutical products market
- 4.3.2 overview of development of major health cosmeceutical products
- 4.3.3 scale of major health cosmeceutical products market
- 4.3.4 earnings of major health cosmeceutical products
- 4.3.5 investment potential of subdivided products of major health cosmeceutical products
 - (1) investment potential of moisturizing makeup drugs
 - (2) investment potential of cream makeup drugs
 - (3) investment potential of whitening makeup drugs
 - (4) investment potential of anti-aging cosmeceuticals
 - (5) investment potential of acne makeup drugs
 - (6) investment potential of exfoliating cosmeceuticals
 - (7) investment potential of other cosmeceuticals
- 4.3.6 forecast of development of major health cosmeceutical products
- 4.4 analysis of investment potential of health products market**
- 4.4.1 overview of development of health products
- 4.4.2 scale of health products market
- 4.4.3 earnings of health products market
- 4.4.4 competitive landscape of health products market
- 4.4.5 risks of investment of health products market
- 4.4.6 investment potential of subdivided products of health products
 - (1) investment potential of health products strengthening the immune system
 - (2) investment potential of health products relieving fatigue
 - (3) investment potential of health products improving sleepiness
 - (4) investment potential of health products of nutritional supplements
 - (5) investment potential of health products of beauty
 - (6) investment potential of health products of weight losing
 - (7) investment potential of health products of lowering blood lipid
 - (8) investment potential of health products of lowering blood glucose
- 4.4.7 forecast of development prospects of health products
- 4.5 analysis of investment potential of herbal tea market**
- 4.5.1 overview of development of herbal tea
- 4.5.2 scale of herbal tea market
- 4.5.3 earnings of herbal tea market
- 4.5.4 competitive landscape of herbal tea market
- 4.5.5 risks of investment of herbal tea market
- 4.5.6 investment potential of of herbal tea products
- 4.5.7 forecast of development prospects of of herbal tea
- 4.6 analysis of investment potential of health equipment market**
- 4.6.1 overview of development of health equipment
- 4.6.2 scale of health equipment market
- 4.6.3 earnings of health equipment market
- 4.6.4 competitive landscape of health equipment market
- 4.6.5 risks of investment of health equipment market
- 4.6.6 investment potential of subdivided products of health equipment
 - (1) investment potential of health equipment of massage

- (2) investment potential of health equipment of body fitness
- (3) investment potential of health equipment of treatment
- (4) investment potential of health equipment of other functions
- 4.6.7 forecast of development prospects of health equipment

Chapter 5: Reference of development experience of foreign massive health industry

5.1 overview of development of the global massive health industry

- 5.1.1 analysis of development course of the global massive health industry
- 5.1.2 analysis of status quo of development of the global massive health industry
- 5.1.3 analysis of overall scale of the global massive health industry
- 5.1.4 analysis of product structure of the global massive health industry
- 5.1.5 analysis of subdivided markets of the global massive health industry

5.2 reference of development experience of massive health industry in developed countries

- 5.2.1 reference of development experience of massive health industry in America
- 5.2.2 reference of development experience of massive health industry in Japan
- 5.2.3 reference of development experience of massive health industry in South Korea
- 5.2.4 reference of development experience of massive health industry in Britain
- 5.2.5 reference of development experience of massive health industry in France
- 5.2.6 reference of development experience of massive health industry in Germany

5.3 reference of experience of leading multinationals into massive health

5.3.1 Abbott

- (1) brief introduction of the company's development
- (2) analysis of the company's operation
- (3) analysis of operation of the company's massive health products
- (4) reference of experience of the company's massive health strategy
- (5) analysis of the company's investment in China

5.3.2 Johnson&Johnson

- (1) brief introduction of the company's development
- (2) analysis of the company's operation
- (3) analysis of operation of the company's massive health products
- (4) reference of experience of the company's massive health strategy
- (5) analysis of the company's investment in China

5.3.3 Novartis AG

- (1) brief introduction of the company's development
- (2) analysis of the company's operation
- (3) analysis of operation of the company's massive health products
- (4) reference of experience of the company's massive health strategy
- (5) analysis of the company's investment in China

5.3.4 Glaxo Smith Kline

- (1) brief introduction of the company's development
- (2) analysis of the company's operation
- (3) analysis of operation of the company's massive health products
- (4) reference of experience of the company's massive health strategy
- (5) analysis of the company's investment in China

5.3.5 Sanofi-Aventis

- (1) brief introduction of the company's development
- (2) analysis of the company's operation
- (3) analysis of operation of the company's massive health products
- (4) reference of experience of the company's massive health strategy
- (5) analysis of the company's investment in China

Chapter 6: Analysis of operation of leading enterprises of China's massive health industry

6.1 analysis of operation of pharmaceutical companies to enter massive health

6.1.1 Tasly Pharmaceutical Group Co., Ltd.

- (1) brief introduction of the company's development
- (2) analysis of the company's operation
 - 1) analysis of major economic indicators
 - 2) analysis of the company's profitability capability
 - 3) analysis of the company's operation capability
 - 4) analysis of the company's solvency capability

- 5) analysis of the company's development capability
 - (3) analysis of the company's massive health products
 - 1) analysis of the company's product structure
 - 2) analysis of the company's massive health products
 - (4) analysis of the company's massive health market
 - (5) analysis of the company's massive health strategy
 - (6) analysis of advantages and disadvantages of the company's massive health strategy
 - (7) analysis of investment, merger and restructuring of the company
 - (8) analysis of the company's latest development trend
- 6.1.2 Yunnan Baiyao Group Co., Ltd.
- (1) brief introduction of the company's development
 - (2) analysis of the company's operation
 - 1) analysis of the company's major economic indicators
 - 2) analysis of the company's profitability capability
 - 3) analysis of the company's operation capability
 - 4) analysis of the company's solvency capability
 - 5) analysis of the company's development capability
 - (3) analysis of the company's massive health products
 - 1) analysis of the company's product structure
 - 2) analysis of the company's massive health products
 - (4) analysis of the company's massive health market
 - (5) analysis of the company's massive health strategy
 - (6) analysis of advantages and disadvantages of the company's massive health strategy
 - (7) analysis of investment, merger and restructuring of the company
 - (8) analysis of the company's latest development trend
- 6.1.3 Beijing Tongrentang Co., Ltd.
- (1) brief introduction of the company's development
 - (2) analysis of the company's operation
 - 1) analysis of major economic indicators
 - 2) analysis of the company's profitability capability
 - 3) analysis of the company's operation capability
 - 4) analysis of the company's solvency capability
 - 5) analysis of the company's development capability
 - (3) analysis of the company's massive health products
 - (4) analysis of the company's massive health market
 - (5) analysis of the company's massive health strategy
 - (6) analysis of advantages and disadvantages of the company's massive health strategy
 - (7) analysis of investment, merger and restructuring of the company
 - (8) analysis of the company's latest development trend
- 6.1.4 Mayinglong Pharmaceutical Group Co., Ltd.
- (1) brief introduction of the company's development
 - (2) analysis of the company's operation
 - 1) analysis of the company's major economic indicators
 - 2) analysis of the company's profitability capability
 - 3) analysis of the company's operation capability
 - 4) analysis of the company's solvency capability
 - 5) analysis of the company's development capability
 - (3) analysis of the company's massive health products
 - 1) analysis of the company's product structure
 - 2) analysis of the company's massive health products
 - (4) analysis of the company's massive health market
 - (5) analysis of the company's massive health strategy
 - (6) analysis of advantages and disadvantages of the company's massive health strategy
 - (7) analysis of investment, merger and restructuring of the company
 - (8) analysis of the company's latest development trend
- 6.1.5 Guangzhou Pharmaceutical Company Limited
- (1) brief introduction of the company's development
 - (2) analysis of the company's operation
 - 1) analysis of major economic indicators

- 2) analysis of the company's profitability capability
- 3) analysis of the company's operation capability
- 4) analysis of the company's solvency capability
- 5) analysis of the company's development capability
- (3) analysis of the company's massive health products
 - 1) analysis of the company's product structure
 - 2) analysis of the company's massive health products
- (4) analysis of the company's massive health market
- (5) analysis of the company's massive health strategy
- (6) analysis of advantages and disadvantages of the company's massive health strategy
- (7) analysis of the company's latest development trend
- 6.1.6 Xiuzheng Pharmaceutical Group
 - (1) brief introduction of the company's development
 - (2) analysis of the company's operation
 - 1) analysis of the company's capabilities of production and marketing
 - 2) analysis of the company's profitability capability
 - 3) analysis of the company's operation capability
 - 4) analysis of the company's solvency capability
 - 5) analysis of the company's development capability
 - (3) analysis of the company's massive health products
 - (4) analysis of the company's massive health market
 - (5) analysis of the company's massive health strategy
 - (6) analysis of advantages and disadvantages of the company's massive health strategy
 - (7) analysis of the company's latest development trend
- 6.1.7 Henan Wanxi Pharmaceutical Co., Ltd.
 - (1) brief introduction of the company's development
 - (2) analysis of the company's operation
 - 1) analysis of the company's capabilities of production and marketing
 - 2) analysis of the company's profitability capability
 - 3) analysis of the company's operation capability
 - 4) analysis of the company's solvency capability
 - 5) analysis of the company's development capability
 - (3) analysis of the company's massive health products
 - 1) analysis of the company's product structure
 - 2) analysis of the company's massive health products
 - (4) analysis of the company's massive health market
 - (5) analysis of the company's massive health strategy
 - (6) analysis of advantages and disadvantages of the company's massive health strategy
 - (7) analysis of the company's latest development trend
- 6.1.8 Sanjing Pharmaceutical Co., Ltd. of Harbin Pharmaceutical Group
 - (1) brief introduction of the company's development
 - (2) analysis of the company's operation
 - 1) analysis of major economic indicators
 - 2) analysis of the company's profitability capability
 - 3) analysis of the company's operation capability
 - 4) analysis of the company's solvency capability
 - 5) analysis of the company's development capability
 - (3) analysis of the company's massive health products
 - (4) analysis of the company's massive health market
 - (5) analysis of the company's massive health strategy
 - (6) analysis of advantages and disadvantages of the company's massive health strategy
 - (7) analysis of investment, merger and restructuring of the company
- 6.1.9 Kunming Dihon Pharmaceutical Co., Ltd.
 - (1) brief introduction of the company's development
 - (2) analysis of the company's operation
 - 1) analysis of the company's capabilities of production and marketing
 - 2) analysis of the company's profitability capability
 - 3) analysis of the company's operation capability
 - 4) analysis of the company's solvency capability

- 5) analysis of the company's development capability
 - (3) analysis of the company's massive health products
 - (4) analysis of the company's massive health market
 - (5) analysis of the company's massive health strategy
 - (6) analysis of advantages and disadvantages of the company's massive health strategy
 - (7) analysis of the company's latest development trend
- 6.1.10 Zhejiang CONBA Pharmaceutical Co., Ltd.
- (1) brief introduction of the company's development
 - (2) analysis of the company's operation
 - 1) analysis of the company's major economic indicators
 - 2) analysis of the company's profitability capability
 - 3) analysis of the company's operation capability
 - 4) analysis of the company's solvency capability
 - 5) analysis of the company's development capability
 - (3) analysis of the company's massive health products
 - 1) analysis of the company's product structure
 - 2) analysis of the company's massive health products
 - (4) analysis of the company's massive health market
 - (5) analysis of the company's massive health strategy
 - (6) analysis of advantages and disadvantages of the company's massive health strategy
 - (7) analysis of investment, merger and restructuring of the company
 - (8) analysis of the company's latest development trend
- 6.1.11 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.
- (1) brief introduction of the company's development
 - (2) analysis of the company's operation
 - 1) analysis of major economic indicators
 - 2) analysis of the company's profitability capability
 - 3) analysis of the company's operation capability
 - 4) analysis of the company's solvency capability
 - 5) analysis of the company's development capability
 - (3) analysis of the company's massive health products
 - 1) analysis of the company's product structure
 - 2) analysis of the company's massive health products
 - (4) analysis of the company's massive health market
 - (5) analysis of the company's massive health strategy
 - (6) analysis of advantages and disadvantages of the company's massive health strategy
 - (7) analysis of investment, merger and restructuring of the company
- 6.1.12 Kangmei Pharmaceutical Co., Ltd.
- (1) brief introduction of the company's development
 - (2) analysis of the company's operation
 - 1) analysis of the company's major economic indicators
 - 2) analysis of the company's profitability capability
 - 3) analysis of the company's operation capability
 - 4) analysis of the company's solvency capability
 - 5) analysis of the company's development capability
 - (3) analysis of the company's massive health products
 - 1) analysis of the company's product structure
 - 2) analysis of the company's massive health products
 - (4) analysis of the company's massive health market
 - (5) analysis of the company's massive health strategy
 - (6) analysis of advantages and disadvantages of the company's massive health strategy
 - (7) analysis of investment, merger and restructuring of the company
- 6.1.13 Guizhou Yibai Pharmaceutical Co., Ltd.
- (1) brief introduction of the company's development
 - (2) analysis of the company's operation
 - 1) analysis of major economic indicators
 - 2) analysis of the company's profitability capability
 - 3) analysis of the company's operation capability
 - 4) analysis of the company's solvency capability

- 5) analysis of the company's development capability
- (3) analysis of the company's massive health products
- (4) analysis of the company's massive health market
- (5) analysis of the company's massive health strategy
- (6) analysis of advantages and disadvantages of the company's massive health strategy
- (7) analysis of investment, merger and restructuring of the company
- 6.1.14 Guizhou Bailing Enterprise Group Pharmaceutical Co., Ltd.
 - (1) brief introduction of the company's development
 - (2) analysis of the company's operation
 - 1) analysis of major economic indicators
 - 2) analysis of the company's profitability capability
 - 3) analysis of the company's operation capability
 - 4) analysis of the company's solvency capability
 - 5) analysis of the company's development capability
 - (3) analysis of the company's massive health products
 - 1) analysis of the company's product structure
 - 2) analysis of the company's massive health products
 - (4) analysis of the company's massive health market
 - (5) analysis of the company's massive health strategy
 - (6) analysis of advantages and disadvantages of the company's massive health strategy
 - (7) analysis of investment, merger and restructuring of the company
 - (8) analysis of the company's latest development trend
- 6.1.15 Henan Taloph Pharmaceutical Co., Ltd.
 - (1) brief introduction of the company's development
 - (2) analysis of the company's operation
 - 1) analysis of major economic indicators
 - 2) analysis of the company's profitability capability
 - 3) analysis of the company's operation capability
 - 4) analysis of the company's solvency capability
 - 5) analysis of the company's development capability
 - (3) analysis of the company's massive health products
 - 1) analysis of the company's product structure
 - 2) analysis of the company's massive health products
 - (4) analysis of the company's massive health market
 - (5) analysis of the company's massive health strategy
 - (6) analysis of advantages and disadvantages of the company's massive health strategy
 - (7) analysis of investment, merger and restructuring of the company
 - (8) analysis of the company's latest development trend
- 6.2 analysis of process of massive health of drugstore chain benchmarking enterprises**
 - 6.2.1 Yunnan Hongxiang Yixintang Pharmaceutical (Group) Co., Ltd.
 - (1) brief introduction of the company's development
 - (2) analysis of the company's operation
 - (3) the company's suppliers and procurement
 - (4) analysis of the company's market expansion
 - (5) quantity and distribution of the company's stores
 - (6) the company's positioning and service object
 - (7) analysis of development of the company's massive health strategy
 - (8) analysis of advantages and disadvantages of the company's massive health strategy
 - (9) analysis of the company's latest development trend
 - 6.2.2 China Nepstar Chain Drugstore Ltd.
 - (1) brief introduction of the company's development
 - (2) analysis of the company's operation
 - (3) the company's suppliers and procurement
 - (4) analysis of the company's market expansion
 - (5) quantity and distribution of the company's stores
 - (6) the company's positioning and service object
 - (7) analysis of progress of the company's massive health
 - (8) analysis of the company's latest development trend
 - 6.2.3 LBX Pharmacy Chain Co., Ltd.

- (1) brief introduction of the company's development
- (2) analysis of the company's operation
- (3) the company's suppliers and procurement
- (4) analysis of the company's market expansion
- (5) quantity and distribution of the company's stores
- (6) the company's positioning and service object
- (7) analysis of progress of the company's massive health
- (8) analysis of the company's latest development trend

6.2.4 Sinopharm National Pharmacy Co., Ltd.

- (1) brief introduction of the company's development
- (2) analysis of the company's operation
- (3) the company's suppliers and procurement
- (4) analysis of the company's market expansion
- (5) quantity and distribution of the company's stores
- (6) the company's positioning and service object
- (7) analysis of progress of the company's massive health
- (8) analysis of the company's latest development trend

6.2.5 Guangdong Dashenling Drugstore Ltd.

- (1) brief introduction of the company's development
- (2) analysis of the company's operation
- (3) the company's suppliers and procurement
- (4) analysis of the company's market expansion
- (5) quantity and distribution of the company's stores
- (6) the company's positioning and service object
- (7) analysis of progress of the company's massive health
- (8) analysis of the company's latest development trend

there are another 6 enterprises

6.3 analysis of operation of benchmarking enterprises of health products

6.3.1 Amway (China) Co. Ltd.

- (1) brief introduction of the company's development
- (2) analysis of the company's operation
 - 1) analysis of major economic indicators
 - 2) analysis of the company's profitability capability
 - 3) analysis of the company's operation capability
 - 4) analysis of the company's solvency capability
 - 5) analysis of the company's development capability
- (3) analysis of the company's product structure
- (4) distribution of the company's regional markets
- (5) analysis of the company's operation strategy
- (6) analysis of advantages and disadvantages of the company's operation
- (7) analysis of investment, merger and restructuring of the company
- (8) analysis of the company's latest development trend

6.3.2 Red Bull Vitamin Drink Co., Ltd.

- (1) brief introduction of the company's development
- (2) analysis of the company's operation
 - 1) analysis of major economic indicators
 - 2) analysis of the company's profitability capability
 - 3) analysis of the company's operation capability
 - 4) analysis of the company's solvency capability
 - 5) analysis of the company's development capability
- (3) analysis of the company's product structure
- (4) distribution of the company's regional markets
- (5) analysis of the company's operation strategy
- (6) analysis of advantages and disadvantages of the company's operation
- (7) analysis of investment, merger and restructuring of the company
- (8) analysis of the company's latest development trend

6.3.3 Joicare Pharmaceutical Group Co., Ltd.

- (1) brief introduction of the company's development
- (2) analysis of the company's operation

- 1) analysis of major economic indicators
- 2) analysis of the company's profitability capability
- 3) analysis of the company's operation capability
- 4) analysis of the company's solvency capability
- 5) analysis of the company's development capability
- (3) analysis of the company's product structure
- (4) distribution of the company's regional markets
- (5) analysis of the company's operation strategy
- (6) analysis of advantages and disadvantages of the company's operation
- (7) analysis of investment, merger and restructuring of the company
- (8) analysis of the company's latest development trend
- 6.3.4 New Era Health Industry (Group) Co., Ltd.
 - (1) brief introduction of the company's development
 - (2) analysis of the company's operation
 - 1) analysis of major economic indicators
 - 2) analysis of the company's profitability capability
 - 3) analysis of the company's operation capability
 - 4) analysis of the company's solvency capability
 - 5) analysis of the company's development capability
 - (3) analysis of the company's product structure
 - (4) distribution of the company's regional markets
 - (5) analysis of the company's operation strategy
 - (6) analysis of advantages and disadvantages of the company's operation
 - (7) analysis of investment, merger and restructuring of the company
 - (8) analysis of the company's latest development trend
- 6.3.5 Perfect (China) Co., Ltd.
 - (1) brief introduction of the company's development
 - (2) analysis of the company's operation
 - 1) analysis of major economic indicators
 - 2) analysis of the company's profitability capability
 - 3) analysis of the company's operation capability
 - 4) analysis of the company's solvency capability
 - 5) analysis of the company's development capability
 - (3) analysis of the company's product structure
 - (4) distribution of the company's regional markets
 - (5) analysis of the company's operation strategy
 - (6) analysis of advantages and disadvantages of the company's operation
 - (7) analysis of investment, merger and restructuring of the company
 - (8) analysis of the company's latest development trend

there are another 5 enterprises

Chapter 7: Advice for investment of China's massive health industry

7.1 analysis of development opportunity of massive health industry

- 7.1.1 analysis of development prospects of massive health industry
- 7.1.2 analysis of advantages of pharmaceutical companies to enter massive health
- 7.1.3 analysis of advantages of pharmaceutical companies to enter massive health

7.2 analysis of risks into massive health industry

- 7.2.1 analysis of risk of product structure
- 7.2.2 analysis of risk of market changes
- 7.2.3 analysis of risk of own operation
- 7.2.4 analysis of risk of product homogeneity

7.3 essential qualities into massive health industry

- 7.3.1 essential qualities for large pharmaceutical companies to develop massive health
- 7.3.2 essential qualities for pharmacies to develop massive health

7.4 advice for investment of China's massive health industry

- 7.4.1 advice for pharmaceutical companies to enter massive health
- 7.4.2 advice for pharmacies to transform to massive health

如需了解报告详细内容，请直接致电前瞻客服中心。

全国免费服务热线：400-068-7188 0755-82925195 82925295 83586158

或发电子邮件：service@qianzhan.com

或登录网站：<https://bg.qianzhan.com/>

我们会竭诚为您服务！